Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion type Assertion NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_head.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion description "[TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_provenance.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion evidence source_evidence_literature NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_provenance.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion SIO_000772 23200980 NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_provenance.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion wasDerivedFrom befree-20150227 NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_provenance.
- NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_assertion wasGeneratedBy ECO_0000203 NP924970.RAigVnx85F128dJzW9hV5qlzICgo77c64gVaP6Ot7agkI130_provenance.